have increasingly suggested that the interplay between the characteristics of the mAb and the nature of its target can influence disposition and elimination. Thus, it is becoming increasingly evident that along with FcRn interactions, consideration of the non-FcRnbased biologic processes active in mAb disposition should be integrated into mAb development and optimization. Herein, we describe how the pharmacokinetics of mAbs can be modulated through FcRn interactions and provide perspectives on interpreting the receptor binding parameters in relation to other mechanisms involved in antibody disposition to aid in guiding mAb development.
Introduction
Over the last two decades, human or humanized monoclonal antibodies (mAbs) have been widely successful as medicinal options in numerous disease indications, including cancer, inflammation, and bone, cardiovascular, and autoimmune conditions (Chan and Carter, 2010; Weiner et al., 2010) . Over 30 antibodies have received FDA approval and hundreds more are currently in clinical development (Tabrizi and Roskos, 2007; Reichert, 2010) . The compelling efficacy of these biologic agents, along with advances in protein engineering and directed evolution strategies, has spurred a tremendous effort to optimize the pharmaceutical properties of mABs (Roopenian and Akilesh, 2007; Presta, 2008) . Tuning the potency and affinity of these agents toward their targets in combination with efforts to optimize their pharmacokinetic/ pharmacodynamics (PK/PD) relationships can lead to molecules having improved safety and efficacy profiles. In addition, reducing the dose and/ or dose frequency improves patient convenience and increases compliance, yielding better therapeutic outcomes. A number of studies have focused on modulating the interaction of mAbs with the neonatal Fc receptor (FcRn) in an effort to advance improvements in these areas (Dall'Acqua et al., 2002 Hinton et al., 2004 Hinton et al., , 2006 Datta-Mannan et al., 2007a ,b, 2012a Yeung et al., 2009; Deng et al., 2010) .
FcRn was first identified in the early to mid-1990s as a protective receptor for IgGs and was proposed to be responsible for the relatively long persistence of IgGs in circulation compared with other endogenous proteins (Ghetie et al., 1996; . With the increase in the development of IgG-based therapeutics, improving the interaction of mAbs with FcRn was a logical approach aimed at modulating their PK/PD properties. Mechanistically, it has been proposed that altering the properties of the IgG-FcRn interaction may influence the intracellular trafficking and partitioning of IgGs, resulting in changes of IgG peripheral clearance and circulating half-life in vivo (Ward et al., 2003 (Ward et al., , 2005 Ober et al., 2004a,b; Prabhat et al., 2004; Goebl et al., 2008) . In this regard, many preclinical studies have focused on understanding aspects of the IgG-FcRn interaction, which can serve as the basis of a rational strategy to guide or inform mAb development. A variety of FcRn binding assays and tools have been developed and used to characterize the interaction with IgGs. However, the ability to define a predictive relationship between the FcRn binding interaction of IgGs in vitro and their pharmacokinetics in vivo broadly across mAbs remains elusive (Gurbaxani et al., 2006; Suzuki et al., 2010; Datta-Mannan et al., 2012a) . Many studies have increasingly demonstrated that an interplay between the characteristics of the antibody (e.g., biophysical properties, antigen affinity, glycosylation, proteolytic stability) and its therapeutic target (membrane-bound or soluble antigen, antigen load) can influence disposition and elimination (Igawa et al., 2010b; Khawli et al., 2010; Yeung et al., 2010; Wang et al., 2011a,b; Bumbaca et al., 2012; Chaparro-Riggers et al., 2012) . From this, it has become apparent that the complexity of biologic processes involved in mAb disposition must be considered, along with the molecule-to-molecule nature of these factors, to rationally guide antibody engineering and development strategies. In this review, we will discuss how the pharmacokinetics of mAbs can be affected by modulation of their interactions with FcRn and attempt to put this binding interaction parameter into perspective with other mechanisms involved in antibody disposition to aid in guiding mAb development.
The Receptor Interaction Assays
FcRn plays an essential role in the regulation of IgG concentrations in circulation by protecting or salvaging IgG from lysosomal degradation and by recycling molecules taken into tissue cells back into the blood (Ghetie et al., 1996; Ward et al., 2003) . A cornerstone of the FcRn:IgG interaction is the tightly regulated, pH-dependent manner in which binding occurs; high binding affinity interactions occur at an acidic pH (pH ;6), whereas there are weak to no observed FcRn:IgG interactions as the pH is raised to neutral (pH 7.4). (Ober et al., 2004a, b; Prabhat et al., 2004; Goebl et al., 2008) . It is largely presumed that after fluid-phase uptake, IgG binding by the receptor occurs in the acidic (pH ;6) microenvironment of the endosomes within cells. Following the interaction at acidic pH, FcRn recycles IgG into circulation upon exposure to physiologic pH (pH ;7.4) (Ward et al., 2003 (Ward et al., , 2005 Ober et al., 2004a,b; Prabhat et al., 2004; Goebl et al., 2008) . IgG that is not bound to FcRn within endosomes undergoes proteolytic degradation in lysosomes (Ward et al., 2003 (Ward et al., , 2005 . Thus, the proportion of IgG processed through recycling versus degradative pathways is believed to be important in determining the clearance and half-life of an IgG in the circulation.
Given the understanding of the mechanism, FcRn-IgG binding assays have focused on the strict pH-dependent nature of the interaction, attempting to optimize the binding affinities at acidic (pH ;5 to 6) and neutral pH (pH ;7.4). Characterizing both aspects of the FcRn-IgG interaction is required to aid in making connections to the potential influence on mAb pharmacokinetics (discussed further in the next section). Techniques and tools developed to characterize both the pH dependency of the interaction and binding affinity include cell-based systems, immunoassays, solution-based approaches, and surface plasmon resonance (SPR). The following paragraphs discuss these tools, the parameters of the FcRn-IgG interaction that these approaches have been predominantly used to characterize or measure, and the advantages and limitations of each approach.
SPR has been the most broadly used format for measuring FcRnIgG interactions. The SPR formats have included covalent coupling of either FcRn (FcRn down method) or IgG (IgG down method) to the surface of a sensor chip and flowing the unconjugated species over the chip surface (Raghavan et al., 1995; Dall'Acqua et al., 2006; Datta-Mannan et al., 2007a; Yeung et al., 2009 ). This approach allows characterization of the interaction at acidic (generally pH ;6) and basic (pH ;7.4 to 8) conditions. Both assay formats yield a number of quantitative parameters that include the rates of association (k on ) and dissociation (k off ), as well as the binding affinity (K D ) of the interaction. The inherent nature of the 2:1 FcRn-IgG binding stoichiometry of the interaction has been proposed as an influence on the degree of avidity observed in the two SPR assay formats. As a result, a number of different K D values have been reported for human IgG binding to both human and cynomolgus monkey at pH 6 depending on the method applied. This has challenged both cross-laboratory comparisons and the systematic correlation of in vitro-to-in vivo outcomes. For example, in our laboratory and in several others (Raghavan et al., 1995; Datta-Mannan et al., 2007a; Wang et al., 2011a) , the K D of the FcRn-IgG interaction was measured in a bivalent Biacore assay (FcRn down), in which antibodies were injected over an FcRn-coated sensor chip. Using this format, the binding affinity of wild-type human IgGs for Although it could be argued that the bivalent assay may better reflect how membrane-anchored FcRn interacts with antibodies in nature, the choice of the FcRn binding assay format fundamentally relates to the nature of the question the interaction is designed to investigate. For example, the bivalent FcRn down format may provide a larger window for studying the dissociation of the receptorantibody complex at neutral pH. A clearer understanding of differences in this parameter may allow a deeper understanding of the consequences for antibody pharmacokinetics (Wang et al., 2011a) . Conversely, the low apparent binding affinity in the monovalent IgG down assay (even at acidic pH) would probably make this dissociation parameter technically difficult to measure accurately at more unfavorable, alkaline pH. Along these lines, Yeung et al. (2009) have proposed that the monovalent FcRn K D derived from the IgG down assay is a more consistent parameter for comparing the extent of affinity improvement across different antibody variants, because it is less sensitive to the IgG's inherent affinity compared with the bivalent format. It is worth noting that the FcRn down assay better recapitulates the intrinsic avidity component in the native FcRn-IgG interaction within cells; therefore, this format may allow a better dissection of the role of IgG affinity versus avidity for FcRn and the relationship of these parameters with antibody clearance. From a pragmatic perspective, the inherent advantages and limitations of the two assay formats with regard to affinity versus avidity should be considered when evaluating data from each assay format. Although the data from the two SPR assay formats each provide useful information, comparison of data across the approaches can also lead to ambiguity and difficulty in quantitative analyses between studies, owing to the inherent caveats of each approach. Thus, applying consistency in the comparison of FcRn binding data within a single assay format for multiple IgGs is an important consideration for making mechanistic connections with their pharmacokinetics.
Irrespective of the SPR assay format applied, binding data at pH 6 and 7.4 represent key parameters that clearly relate to in vivo pharmacokinetic outcomes. For example, a number of investigators have reported that binding to the receptor at neutral pH is negatively correlated with IgG clearance and half-life in vivo, regardless of the antibody binding affinity for FcRn at pH 6 Datta-Mannan et al., 2007a; Yeung et al., 2009) . Similarly, studies show that FcRn knockout mice or IgGs with mutations in the Fc region that clearly ablate FcRn binding at acidic pH also display poor pharmacokinetic properties (Ghetie et al., 1996; Christianson et al., 1997; West and Bjorkman, 2000; Deng et al., 2010) . Given the tight connection to poor kinetic outcomes in vivo, SPR assay formats provide a rapid screen for eliminating antibodies that show no binding to the receptor at pH 6 or do interact with FcRn at neutral pH. Additional assay formats, including immunoassays and cell-based approaches, have also yielded similar information in regard to these negative FcRn interaction properties (Hinton et al., 2004; Datta-Mannan et al., 2007a; Mathur et al., 2013) . A theoretical advantage of the SPR assay format, aside from determination of binding affinity, is the possibility of mining the data to discern quantitative subtleties in the rates of association and dissociation. However, a broad predictive relationship between any of the FcRn interaction parameters (k on , k off , and K D ) in vitro with antibody pharmacokinetics in vivo has remained elusive.
In addition to the direct FcRn binding assays, a few approaches have also been used to probe the pH-dependent dissociation parameters, which have been proposed to better recapitulate the transition of pH conditions the receptor-IgG complex is exposed to at various points during intracellular trafficking. Immunoassays and solution-based interaction strategies have been applied to monitor the extent of preformed FcRn-IgG complex dissociation after exposure to an increasing pH gradient (Datta-Mannan et al., 2007a,b) . These assays were useful for understanding the rapid clearance of a set of antibodies that bound to FcRn at pH 6, yet showed no direct binding to FcRn at neutral pH dmd.aspetjournals.org (Datta-Mannan et al., 2007a,b) . In this case, after formation of the receptor-IgG complexes the IgGs showed an inability to separate from the receptor when exposed to basic pH (Datta-Mannan et al., 2007a,b) . The rapid in vivo peripheral clearance of the IgGs was mechanistically attributed to the lack of dissociation of the receptor complex when exposed to physiologic conditions (Datta-Mannan et al., 2007a,b) . In such a circumstance, the IgG is postulated to be trapped in a pathway of futile recycling. With the complex incapable of dissociation at the cell surface, the in vivo outcome is similar to that observed for the negative effect of antibodies directly associating with FcRn at neutral pH. It is worth noting that although these are less well studied parameters than the direct binding interactions by SPR (and other methods), this more detailed characterization may provide useful insight into aspects of receptor complex binding equilibrium that may represent more closely processes that exist during initial cellular internalization, endosomal sorting, and release into the circulation.
Although the methods discussed above leverage the soluble form of FcRn to probe interactions with antibodies, there are also a few examples of cell-based receptor assays used for studying interactions with IgGs. Generally, the cell-based assays have been used to either qualitatively describe FcRn-mediated antibody intracellular trafficking or quantitate receptor-IgG interaction parameters. The qualitative assays have been valuable for better delineating the mechanism of action of the receptor and its influence on IgG disposition (Ward et al., 2003 (Ward et al., , 2005 Ober et al., 2004a,b; Prabhat et al., 2004; Goebl et al., 2008) ; however, because of the descriptive nature of these results, the qualitative assays are oftentimes difficult to use to make comparisons around receptor interactions across a large number of IgG molecules. Thus, quantitative cell-based binding assays are frequently used to measure receptor-IgG interactions. However, some of these assays use engineered cell lines with FcRn constitutively expressed on the membrane surface for studying receptor-IgG interactions (Hinton et al., 2004 (Hinton et al., , 2006 Mathur et al., 2013) . Similarly to the studies with soluble FcRn, the quantitative cell-based assays have been used to examine the relative FcRn binding affinity and the pH-dependency of interactions in the context of: mutations within the Fc region IgGs, various biochemical/biophysical properties of IgGs (e.g., influence of IgG aggregation, methionine oxidation), and the effect of IgG subclass and other molecular attributes of IgGs (i.e., effect of Fab region) on FcRn (Hinton et al., 2004 (Hinton et al., , 2006 Mathur et al., 2013) . Although there are no published data that directly compare an antibody molecule(s) in quantitative cell assays with the soluble receptor formats, data from both types of assays would suggest the conclusions around the IgG parameters that affect FcRn binding are similar; however, the sensitivity of the assays to detect/discern the binding parameters is currently a gap in our understanding. It is theoretically plausible that compared with the assays that use soluble FcRn, the quantitative cell-based approaches may be advantageous because the manner in which FcRn is presented is closer to its physiologic or native state. Thus, these methods may also lend a more complete understanding of IgG interactions with FcRn in the context of other IgG interactions that may occur with glycans and/or other components of the cellular membrane as a result of their stereochemical nature or charge distribution properties. However, it should be noted that since the validated quantitative cell assays measure FcRn interactions with antibodies at the plasma membrane surface, they do not fully recapitulate intracellular endosomal trafficking that IgGs undergo when interacting with the receptor.
Applications and Interpretations of FcRn Binding Assays toward Understanding mAb Pharmacokinetics
It is clear that FcRn binding assays have been useful in providing information around the properties of the IgG-FcRn interaction that have significant negative consequence for mAb PK properties in vivo Datta-Mannan et al., 2007a; Yeung et al., 2009) . As previously mentioned, what is less understood are the influences of subtleties in this interaction on in vivo behavior. Since these "aberrant" receptor binding properties have only been reported in the context of mutations to the Fc region of IgGs, it is really in the environment of antibody engineering or optimization that the pharmaceutical industry has attempted to apply binding assays and develop a better understanding of how these in vitro interactions relate to IgG pharmacokinetics in vivo (Dall'Acqua et al., 2002 Hinton et al., 2004 Hinton et al., , 2006 Datta-Mannan et al., 2007a,b; Yeung et al., 2009 Yeung et al., , 2010 Deng et al., 2010) . However, in isolation, the characterization of the IgG-FcRn interaction often provides limited insight into the desired in vivo properties of a therapeutic antibody (Datta-Mannan et al., 2012a) . It has been established that the biophysical and chemical properties of IgGs, including deamidation, oxidation, charge distribution, and post-translational modifications, influence in vivo behavior whether related or unrelated to their FcRn interaction (Igawa et al., 2010a; Khawli et al., 2010; Yeung et al., 2010; Wang et al., 2011a,b) . The complexity and interaction of these multiple factors influencing the in vivo behavior of therapeutic antibodies must be understood to facilitate rational protein engineering strategies. In addition, the implications of these studies are broad and extend into IgG expression and purification control strategies along with additional chemistry, manufacturing, and controls considerations, including handling and storage of mAb therapeutics. With this perspective in mind, we will discuss characteristics of antibody structure, the biologic target, and the nature of mAb-antigen interaction as factors that need to be considered in an integrative manner with FcRn binding to better modulate mAb PK/PD properties.
Although the utility of FcRn binding assays for the development of Fc-variant mAbs with improved pharmacokinetics is incontrovertible, discrepancies in the in vitro FcRn binding affinity-pharmacokinetic relationship make the predictive quantitative translation across antibodies and their target antigens somewhat tenuous. Along these lines, retrospective analyses of several humanized mAbs having similar human FcRn binding properties demonstrated that they had ;1.5-to ;2-fold differences in their elimination half-lives in humans, suggesting a lack of a direct quantitative correlation with FcRn binding (Suzuki et al., 2010) . Similarly, Gurbaxani et al. (2006) were unable to directly correlate FcRn binding affinity to the pharmacokinetics of a number of IgGs in mice. There are certainly a number of preclinical reports that have shown that specific Fc variants (T250Q/M428L, V308P, M428L, M252Y/S254T/T256E, M428L/N434S, N434A, N434H) that improve IgG affinity for FcRn at pH 6 can result in ;2-to ;4-fold longer in vivo elimination-phase half-lives in either cynomolgus or rhesus monkeys (Dall'Acqua et al., 2002 Datta-Mannan et al., 2007a,b; Deng et al., 2010; Hinton et al., 2004 Hinton et al., , 2006 Yeung et al., 2009 Yeung et al., , 2010 . This general relationship also has been validated more recently in humans with the M252Y/S254T/T256E set of mutations (YTE) constructed on the Fc of antirespiratory syncytial virus (Robbie et al., 2013) . However, the quantitative correlation of FcRn affinity improvement with in vivo pharmacokinetic parameters also has been ambiguous in primate studies of engineered mAbs (Hinton et al., 2004; Yeung et al., 2009; Deng et al., 2010; Datta-Mannan et al., 2012a) . Deng et al. (2010) showed that an anti-tumor necrosis factor-a mAb Fc variant (N434H) with ;3-fold higher FcRn affinity at pH 6 had similar pharmacokinetics in cynomolgus monkeys compared to a lower receptor affinity variant constructed on the same mAb backbone (N434A), although these findings may have been compromised by antidrug antibodies (ADA). In another set of examples, Fc mutations (M252Y/ S254T/T256E) that increased receptor binding at pH 6 by ;10-fold have shown ;3-to 4-fold improvements in mAb half-life in monkeys dmd.aspetjournals.org (Dall'Acqua et al., 2006) , whereas Fc mutations (T250Q/M428L) that display ;30 fold-increase in FcRn binding have shown only ;2.5-fold improvement in half-life (Hinton et al., 2004 (Hinton et al., , 2006 . As discussed above, one of the challenges in establishing a systematic understanding of the FcRn affinity-pharmacokinetic relationship is the different methodologies and technologies used to measure IgG-FcRn interactions, thereby complicating a direct comparison of binding properties between studies. Even in cases where these attributes are well understood, there is still a quantitative and qualitative discrepancy in the in vitro-in vivo relation, indicating that there are probably additional factors or properties of the mAbs along with their FcRn affinity that influence the in vivo pharmacokinetics (Gurbaxani et al., 2006 (Gurbaxani et al., , 2013 Suzuki et al., 2010; Datta-Mannan et al., 2012a) .
Indeed, a number of inconsistent reports regarding the relationship between in vitro FcRn binding data and mAb pharmacokinetics are not readily explained by the simple set of FcRn interaction parameters at acidic and basic pHs. It is entirely possible that in some instances the observed in vitro FcRn affinity differences may have been attributable to assay artifacts such as Fab interactions with the receptor and/or highly charged or hydrophobic regions within the IgG facilitating nonFc attributable FcRn binding. It is difficult to readily discern the contributions of receptor interaction artifacts on in vitro-to-in vivo inconsistencies within the literature given the number of isolated reports. However, it seems reasonable to suggest that, in isolation, measurement of the absolute affinity of the IgG-FcRn interaction provides little insight into in vivo pharmacokinetic properties.
A recent systematic assessment of 15 mAbs demonstrated that a priori prediction of pharmacokinetic properties, based solely on the FcRn in vitro affinity-in vivo pharmacokinetic relationship, was not possible (Datta-Mannan et al., 2012a) . Thus, it is logical to conclude that in some cases the relative contribution of other factors affecting IgG disposition in vivo are critical to interpreting this property to further mAb development. The most obvious is the case of specific target-mediated mAb disposition. In these instances, the preferential mAb-binding interaction in vivo is to its particular target antigen (i.e., receptor or membraneassociated antigen) at the surface of the cell membrane. Since the mAb binds antigen at the cell surface and the interaction is typically of high affinity (picomolar to low nanomolar), the mAb's disposition will be governed through this specific cellular interaction as opposed to the generic FcRn salvage mechanism. At nonsaturating concentrations, the target-mediated internalization of the mAb from the peripheral circulation is the major pathway of mAb elimination that minimizes the contribution of the FcRn pathway. As the mAb concentrations increase, target-mediated disposition becomes saturated, unmasking the contribution of FcRn-to-mAb disposition. In addition, the inherent properties of antigen (such as its turnover, concentration, expression pattern, tissue distribution) will be a major dictator of mAb disposition, overriding the influence of FcRn-mediated salvage. These phenomena were observed in a baboon pharmacokinetic study of a humanized anti-CD4 antibody with a single Fc substitution (N434H) designed to improve its binding to FcRn relative to its wild-type mAb equivalent (Zheng et al., 2011) . The authors contended that at nonsaturating concentrations, CD4 receptor-mediated internalization was the major elimination pathway for the variant mAb (Zheng et al., 2011) . As the antibody concentration increased, the CD4 receptors became saturated and an ;2-fold slower clearance of the variant IgG was observed compared with its wild-type counterpart (Zheng et al., 2011) . The slower clearance of the variant mAb was attributed to its enhanced FcRn interactions, which became a greater part of the total mAb elimination following antigen saturation. Additionally, for mAbs that target soluble antigens, it is entirely possible that the mAb binding affinity for FcRn is different when they are bound to antigen. In some instances it may be possible that the complex has a reduced FcRn affinity that leads to target-mediated mAb elimination. This was hypothesized in a recent study for a PCSK9 mAb (ChaparroRiggers et al., 2012) . If the soluble antigen is present in high concentrations in the blood and/or has a high rate of turnover, such as in the case of PCSK9, clearance of the complex via reduced FcRn binding will be a major contributor to the mAb elimination (ChaparroRiggers et al., 2012) . Thus, in some instances measuring the FcRn binding affinity of mAb-antigen complex may provide insight into the translation to in vivo observations. Taken together, these examples illustrate that a firm understanding of the biology of the target is critical to understanding how in vitro FcRn binding data can be used to guide mAb development.
Although the interplay of target-mediated mAb clearance mechanisms contributes to some of the pharmacokinetic discrepancies observed with the FcRn binding assays in the aforementioned examples, a number of studies with Fc-engineered mAbs have employed in vivo systems with low or no endogenous antigen or mAb doses that saturated the target (Dall'Acqua et al., 2002; Hinton et al., 2004; Yeung et al., 2009; DattaMannan et al., 2012a) . Antibodies directed toward low-expression soluble targets or given at high doses more probably will show improved pharmacokinetic properties with Fc engineering, as in the case of the engineered antirespiratory syncytial virus mAb (Dall'Acqua et al., 2006) . Despite this, recent reports also have identified other non-FcRn clearance pathways and mAb biochemical characteristics that can significantly impact mAb disposition (Igawa et al., 2010b; Khawli et al., 2010; Yeung et al., 2010; Wang et al., 2011a,b) . These studies have suggested that factors including the pI/charge patches, stability and aggregation potential, post-translational modifications, and the characteristics of the Fab region can all have significant impact on antibody disposition. These molecular characteristics may in themselves influence mAb structure so as to alter the "true" interaction with FcRn in vivo, or may contribute to nonspecific cell surface binding that alters the rate of endocytosis and the relative proportion of FcRn-mediated recycling. Given the multiplicity of factors that influence mAb disposition in vivo, the interpretation of FcRn binding data in isolation can be inappropriate to guide mAb development. Thus, in addition to FcRn-binding assays being used to guide mAb development, additional non-FcRn determinants and antibody characteristics will need to be considered for integrated data-driven decision making. Even with this approach, it is probable that a priori prediction of the pharmacokinetic outcomes will remain difficult. Despite the gap with using FcRn binding assays and data to predict mAb pharmacokinetic outcomes, the assays have been useful for retrospective analyses of factors that affect mAb clearance. For example, in one study a close association between in vitro FcRn dissociation at neutral pH of mAbs with the same Fc and different Fab regions and their in vivo pharmacokinetics was useful for delineating the Fab domain effects on FcRn binding (Wang et al., 2011a) . In another study, FcRn binding assays were useful for demonstrating that methionine oxidation in the Fc region can reduce FcRn binding and lead to an increased peripheral clearance of mAbs (Wang et al., 2011b) . Thus, profiling the FcRn binding properties of mAbs with various conformational and/or physiochemical changes in conjunction with mAb pharmacokinetics can be a useful approach for establishing the contribution of receptor interactions with these parameters to mAb disposition in vivo. These parameters can then be monitored, especially during the manufacture and storage of mAbs, to develop criteria and ranges for receptor binding values that affect mAb disposition.
Leveraging FcRn Binding Assays in an Integrated Manner
In the context of mAbs exhibiting significant target-mediated disposition or nonoptimal biophysical characteristics (as discussed above), FcRn may not be a major driving force determining overall disposition parameters. As such, modulating the IgG-FcRn interaction may yield little to no benefit from a PK/PD perspective unless the impact of these specific or nonspecific pathways is considered. Optimizing the potential benefit from improving the FcRn interaction probably requires integration with engineering aimed at altering target-receptor interactions and improving biochemical and biophysical properties.
Toward this concept, recent research has used combined engineering approaches to modulate both the target and FcRn interactions, yielding antibodies with improved in vivo PK/PD properties. For example, an anti-interleukin-6 receptor (IL-6R) antibody was designed to rapidly dissociate from both soluble/shed and membrane-bound IL-6R within the acidic environment of the endosome (pH 6.0) while maintaining its binding affinity to IL-6R in plasma or at the cell surface (pH 7.4) (Igawa et al., 2010a) . Two distinct engineering opportunities were demonstrated in this example (Igawa et al., 2010a (Igawa et al., , 2013 . In the context of the cell-surface receptor interaction, altered cellular trafficking allowed the mAb to be released from the receptor and subsequently associate with FcRn and be recycled instead of degraded (Igawa et al., 2010a) . Once the balance of pH-dependent association with the receptor was resolved, engineering to improve FcRn binding yielded improved recycling and, in turn, the PK/PD properties of the molecule (Igawa et al., 2010a (Igawa et al., , 2013 . Similarly, the pH-sensitive, engineered IL-6R mAb was able to "unload/dump" soluble/shed receptor that became associated with the mAb, resulting in the recycling of naked antibody capable of rebinding to the cell surface IL6R and prolonging its functional activity (Igawa et al., 2010a) . The validation of such an approach also was demonstrated by an mAb engineered for pH-sensitive binding to proprotein convertase subtilisin/kexin type 9 (PCSK9), a soluble protein with high turnover in rodents and primates. In this case, the authors proposed that the manner or epitope by which this particular mAb bound antigen reduced its ability to be salvaged by FcRn once bound to its target (ChaparroRiggers et al., 2012) . Engineering for pH-sensitive antigen binding served to indirectly leverage the FcRn pathway, resulting in "productive" recycling of noncomplexed mAb, unmasking the true benefit of optimization of the FcRn salvage pathway (Chaparro-Riggers et al., 2012) . Taken together, these examples illustrate the advantages that an integrated mAb engineering approach may have in yielding the next generation of improved antibody therapeutics.
Summary and Future Perspectives
On the basis of a preponderance of the literature, it is clear that FcRn is critical to maintenance of IgG homeostasis, but it is also evident that an engineering strategy based exclusively on modulating the interaction of IgG with FcRn may be insufficient to lead to improved PK/PD properties of therapeutic antibodies. In addition to this interaction, it is important to understand in a holistic manner the interplay between aspects of non-FcRn clearance pathways, such as those mediated by an mAbs' target, the nature of the target itself (e.g., soluble, membrane bound), as well as the biophysical characteristics of the IgG, to determine the balance between these and FcRn in affecting the molecules' disposition. Recent studies have demonstrated that combined engineering approaches addressing the interaction characteristics of the Fc and Fab can be successfully leveraged to provide unique benefit from a PK/PD perspective, and this may be the next path to improved therapeutic properties of this class of molecules. Modeling and simulation also has provided insight into properties required to improve mAb pharmacokinetics, but these efforts need additional integration of the kinetics of membrane-receptor turnover, cellular pathways, and the influence of the intracellular environment on mAb-receptor interactions. Whether all factors can be appropriately accounted for to prospectively guide engineering strategies requires additional studies attempting to refine the parameters most relevant to accurate in vitro-in vivo correlation and prediction.
